AZN (AstraZeneca) Common Stock : $388 Mil (As of Sep. 2024)

View and export this data going back to 1993. Start your Free Trial

What is AstraZeneca Common Stock?

AstraZeneca's quarterly common stock stayed the same from Mar. 2024 ($388 Mil) to Jun. 2024 ($388 Mil) and stayed the same from Jun. 2024 ($388 Mil) to Sep. 2024 ($388 Mil).

AstraZeneca's annual common stock stayed the same from Dec. 2021 ($387 Mil) to Dec. 2022 ($387 Mil) but then increased from Dec. 2022 ($387 Mil) to Dec. 2023 ($388 Mil).

AstraZeneca Common Stock Historical Data

The historical data trend for AstraZeneca's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Common Stock Chart

AstraZeneca Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

328.00

387.00

388.00

AstraZeneca Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Common Stock	Get a 7-Day Free Trial															387.00	388.00	388.00	388.00	388.00

AstraZeneca Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

AstraZeneca Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (NAS:AZN) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

AZNCF:USA AZN:Sweden AZNN:Mexico AZNl:UK AZN:UK ZEGA:Germany ZEG:Germany ZEG:Germany ZEG:Germany ZEGA:Germany ZEG:Germany A1ZN34:Brazil ZEG:Bulgaria AZN:Argentina

Address

1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA

Website

https://www.astrazeneca.com

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.